Preclinical Evaluation of Amphihevir, a First-in-Class Clinical Hepatitis C Virus NS4B Inhibitor-Reference-Cited by-同舟云学术

Preclinical Evaluation of Amphihevir, a First-in-Class Clinical Hepatitis C Virus NS4B Inhibitor

Published:2019-12 Issue:12 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tao Xin¹,Wang Ningyu²,Wang Jianfei³,Fu Zhifei³,Gu Zhengxian³,Zhang Yang³,Chen Shuhui³,Wang Lichun¹,Yu Luoting¹

Affiliation:

1. State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China

2. School of Life Science and Engineering, Southwest JiaoTong University, Chengdu, China

3. WuXi AppTec (Shanghai) Co., Ltd., Shanghai, China

Abstract

Amphihevir, a benzofuran derivative, is the first reported hepatitis C virus (HCV) nonstructural protein 4B (NS4B) inhibitor that has advanced to clinical trials (currently in phase Ib trial [CTR20170632]). Here, we report the results of a preclinical study of its potency, toxicity, selectivity, drug metabolism and pharmacokinetics (DMPK), and safety profiles.

Funder

Changzhou Yinsheng Pharmaceutical Co., Ltd.

The 13th Five-Year National S&T Major Special Project on Major New Drug Innovations

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01237-19

Reference32 articles.

1. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

2. Natural history of liver fibrosis progression in patients with chronic hepatitis C